These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37065739)

  • 1. Adverse cardiovascular effect following gonadotropin-releasing hormone antagonist versus GnRH agonist for prostate cancer treatment: A systematic review and meta-analysis.
    Gu L; Li X; Liu W
    Front Endocrinol (Lausanne); 2023; 14():1157857. PubMed ID: 37065739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.
    Abufaraj M; Iwata T; Kimura S; Haddad A; Al-Ani H; Abusubaih L; Moschini M; Briganti A; Karakiewicz PI; Shariat SF
    Eur Urol; 2021 Jan; 79(1):44-53. PubMed ID: 32605859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study.
    Chen DY; Su PJ; See LC; Liu JR; Chuang CK; Pang ST; Tseng CN; Chen SW; Hsieh IC; Chu PH; Lin YC; Hsu CL; Chang JW; Lin MS; Pang JS; Hsieh MJ; Huang WK
    Prostate; 2021 Sep; 81(12):902-912. PubMed ID: 34196430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular Morbidity in a Randomized Trial Comparing GnRH Agonist and GnRH Antagonist among Patients with Advanced Prostate Cancer and Preexisting Cardiovascular Disease.
    Margel D; Peer A; Ber Y; Shavit-Grievink L; Tabachnik T; Sela S; Witberg G; Baniel J; Kedar D; Duivenvoorden WCM; Rosenbaum E; Pinthus JH
    J Urol; 2019 Dec; 202(6):1199-1208. PubMed ID: 31188734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Proteomics: A Post Hoc Analysis from a Phase II Randomized Clinical Trial Comparing GnRH Antagonist vs GnRH Agonist among Men with Advanced Prostate Cancer.
    Lifshitz K; Ber Y; Shenhar C; Nillson J; Peer A; Rosenbaum E; Baniel J; Kedar D; Ben Zadok OI; Margel D
    J Urol; 2021 Oct; 206(4):952-959. PubMed ID: 34032505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiac biomarkers in patients with prostate cancer and cardiovascular disease receiving gonadotrophin releasing hormone agonist vs antagonist.
    Margel D; Ber Y; Peer A; Shavit-Grievink L; Pinthus JH; Witberg G; Baniel J; Kedar D; Rosenbaum E
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):177-185. PubMed ID: 32737420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist.
    Albertsen PC; Klotz L; Tombal B; Grady J; Olesen TK; Nilsson J
    Eur Urol; 2014 Mar; 65(3):565-73. PubMed ID: 24210090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat].
    Anderson D; Lehmann J; Ecker T; Vosgerau S; Donatz V
    Urologe A; 2017 Jul; 56(7):917-924. PubMed ID: 28405705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular risk of gonadotropin-releasing hormone antagonist versus agonist in men with prostate cancer: an observational study in Taiwan.
    Shao YJ; Hong JH; Chen CK; Huang CY
    Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):722-729. PubMed ID: 35662291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice.
    Davey P; Kirby MG
    World J Urol; 2021 Feb; 39(2):307-315. PubMed ID: 32979057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women.
    Chen H; Xiao L; Li J; Cui L; Huang W
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD008018. PubMed ID: 30827035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
    Higano CS
    Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
    George DJ; Dearnaley DP
    Future Oncol; 2021 Nov; 17(33):4431-4446. PubMed ID: 34409852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].
    Tschöpe C; Kherad B; Spillmann F; Schneider CA; Pieske B; Krackhardt F
    Herz; 2016 Dec; 41(8):697-705. PubMed ID: 27083586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing the risk of cardiovascular disease following GnRH agonist and GnRH antagonist therapy for patient with prostate cancer: a systematic review and meta-analysis.
    Ma C; Abeysekera IR; Xu W; Wang Y; Peng J; Li H
    Minerva Urol Nephrol; 2021 Jun; 73(3):276-282. PubMed ID: 33242948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen deprivation therapy and side effects: are GnRH antagonists safer?
    Freedland SJ; Abrahamsson PA
    Asian J Androl; 2021; 23(1):3-10. PubMed ID: 32655041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?].
    Merseburger AS; Sedding D; Hüter K
    Urologe A; 2016 Feb; 55(2):218-25. PubMed ID: 26637324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer.
    Cirne F; Aghel N; Petropoulos JA; Klotz L; Lenihan DJ; Saad F; Pinthus J; Leong DP
    Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):253-262. PubMed ID: 33470403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis.
    Kunath F; Borgmann H; Blümle A; Keck B; Wullich B; Schmucker C; Sikic D; Roelle C; Schmidt S; Wahba A; Meerpohl JJ
    BMJ Open; 2015 Nov; 5(11):e008217. PubMed ID: 26567252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.